Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) (NCT06116682)
A Phase II Study of Amivantamab SC (Subcutaneous) in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
🩺 Plain-English Summary (8th-Grade Level)
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Who can join: Review the eligibility criteria below.
Location: NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (248 Sites)
Showing the first 25 of 248 sites.
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Sutter Auburn Faith Hospital — Auburn, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Palo Alto Medical Foundation-Fremont — Fremont, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Loma Linda University Medical Center — Loma Linda, California
- Memorial Medical Center — Modesto, California
- Palo Alto Medical Foundation Health Care — Palo Alto, California
- Eisenhower Medical Center — Rancho Mirage, California
- Sutter Roseville Medical Center — Roseville, California
- Sutter Medical Center Sacramento — Sacramento, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- California Pacific Medical Center-Pacific Campus — San Francisco, California
- Mills Health Center — San Mateo, California
- Sutter Pacific Medical Foundation — Santa Rosa, California
- Palo Alto Medical Foundation-Sunnyvale — Sunnyvale, California
- Sutter Solano Medical Center/Cancer Center — Vallejo, California
- Rocky Mountain Regional VA Medical Center — Aurora, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
- Memorial Hospital North — Colorado Springs, Colorado
- Poudre Valley Hospital — Fort Collins, Colorado
- Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
- UCHealth Greeley Hospital — Greeley, Colorado
- Medical Center of the Rockies — Loveland, Colorado
📞 Contact the Study Coordinator
Phone: (870) 936-7066
Email: Emily.Carvell@bmhcc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Non-Small Cell Carcinoma
- CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer — Los Angeles, California
- Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer — Buffalo, New York
- Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer — Jonesboro, Arkansas
- Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study — San Francisco, California
- Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study — Houston, Texas
- Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer — Buffalo, New York
Explore by condition: All Lung Non-Small Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.